ClearRead +Confirm software receives FDA clearance

Editorial Staff | | Health Imaging | Screening

The FDA has given 510(k) clearance to Riverain Technologies’ ClearRead +Confirm software, which is designed to improve chest x-ray clarity and aid in proper placement of tubes, lines and wires.

ClearRead +Confirm selectively increases contrast and suppresses clavicles and ribs in conventional chest x-ray images that can create obstacles and obscure visibility of feeding, drug delivery and pain management tubes, lines and cardiac wires.

A Georgetown University reader study of 334 chest x-rays found reading time was reduced approximately 19 percent using the software without compromising accuracy, according to Dayton, Ohio-based Riverain Technologies.

Editorial Staff

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.